Cargando…

Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye

BACKGROUND AND PURPOSE: Prolonging the drug release can be a suitable approach to overcome the challenges related to topical ophthalmic administration of drugs especially the ones prescribed for chronic ailments. The sustained delivery of the drug would reduce the required frequency of administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzaeei, Shahla, Faryadras, Fatemeh Bahrami, Mehrandish, Saba, Rezaei, Leila, Daneshgar, Farid, Karami, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661680/
https://www.ncbi.nlm.nih.gov/pubmed/36386485
http://dx.doi.org/10.4103/1735-5362.355196
_version_ 1784830532122574848
author Mirzaeei, Shahla
Faryadras, Fatemeh Bahrami
Mehrandish, Saba
Rezaei, Leila
Daneshgar, Farid
Karami, Ahmad
author_facet Mirzaeei, Shahla
Faryadras, Fatemeh Bahrami
Mehrandish, Saba
Rezaei, Leila
Daneshgar, Farid
Karami, Ahmad
author_sort Mirzaeei, Shahla
collection PubMed
description BACKGROUND AND PURPOSE: Prolonging the drug release can be a suitable approach to overcome the challenges related to topical ophthalmic administration of drugs especially the ones prescribed for chronic ailments. The sustained delivery of the drug would reduce the required frequency of administration which could extremely improve patient compliance and feeling of well-being. This study aimed to develop nanofibrous inserts for sustained ophthalmic delivery of timolol maleate (TIM) for the treatment of glaucoma. EXPERIMENTAL APPROACH: Polycaprolactone-based nanofibers containing TIM were prepared using pure polycaprolactone or a blend of it with cellulose acetate or Eudragit RL100 polymers by the electrospinning method. Following the preparation, polymeric inserts were evaluated for morphological and physicochemical properties. The in vitro drug release was assessed and the in vivo efficacy of a selected insert in decreasing the intraocular pressure (IOP) was also evaluated in the equine eyes. FINDINGS / RESULTS: Prepared nanofibers indicated diameter ranged between 122-174 nm. The formulations showed suitable physicochemical properties and stability for ophthalmic administration. In vitro release study showed prolonged release of drug during more than 3 days. In vivo evaluation revealed that the prepared insert is non-irritant and non-toxic to the equine eyes while having suitable efficacy in decreasing the IOP during 6 days. CONCLUSIONS AND IMPLICATION: Prepared TIM inserts indicated a higher efficacy than commercial TIM eye drop in lowering IOP during a prolonged period. Thus, these formulations can be considered suitable for enhancing patient compliance by reducing the frequency of administration in the treatment of glaucoma.
format Online
Article
Text
id pubmed-9661680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96616802022-11-15 Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye Mirzaeei, Shahla Faryadras, Fatemeh Bahrami Mehrandish, Saba Rezaei, Leila Daneshgar, Farid Karami, Ahmad Res Pharm Sci Original Article BACKGROUND AND PURPOSE: Prolonging the drug release can be a suitable approach to overcome the challenges related to topical ophthalmic administration of drugs especially the ones prescribed for chronic ailments. The sustained delivery of the drug would reduce the required frequency of administration which could extremely improve patient compliance and feeling of well-being. This study aimed to develop nanofibrous inserts for sustained ophthalmic delivery of timolol maleate (TIM) for the treatment of glaucoma. EXPERIMENTAL APPROACH: Polycaprolactone-based nanofibers containing TIM were prepared using pure polycaprolactone or a blend of it with cellulose acetate or Eudragit RL100 polymers by the electrospinning method. Following the preparation, polymeric inserts were evaluated for morphological and physicochemical properties. The in vitro drug release was assessed and the in vivo efficacy of a selected insert in decreasing the intraocular pressure (IOP) was also evaluated in the equine eyes. FINDINGS / RESULTS: Prepared nanofibers indicated diameter ranged between 122-174 nm. The formulations showed suitable physicochemical properties and stability for ophthalmic administration. In vitro release study showed prolonged release of drug during more than 3 days. In vivo evaluation revealed that the prepared insert is non-irritant and non-toxic to the equine eyes while having suitable efficacy in decreasing the IOP during 6 days. CONCLUSIONS AND IMPLICATION: Prepared TIM inserts indicated a higher efficacy than commercial TIM eye drop in lowering IOP during a prolonged period. Thus, these formulations can be considered suitable for enhancing patient compliance by reducing the frequency of administration in the treatment of glaucoma. Wolters Kluwer - Medknow 2022-09-08 /pmc/articles/PMC9661680/ /pubmed/36386485 http://dx.doi.org/10.4103/1735-5362.355196 Text en Copyright: © 2022 Research in Pharmaceutical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Mirzaeei, Shahla
Faryadras, Fatemeh Bahrami
Mehrandish, Saba
Rezaei, Leila
Daneshgar, Farid
Karami, Ahmad
Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title_full Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title_fullStr Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title_full_unstemmed Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title_short Development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
title_sort development and evaluation of polycaprolactone-based electrospun nanofibers containing timolol maleate as a sustained-release device for treatment of glaucoma: in vivo evaluation in equine eye
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661680/
https://www.ncbi.nlm.nih.gov/pubmed/36386485
http://dx.doi.org/10.4103/1735-5362.355196
work_keys_str_mv AT mirzaeeishahla developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye
AT faryadrasfatemehbahrami developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye
AT mehrandishsaba developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye
AT rezaeileila developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye
AT daneshgarfarid developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye
AT karamiahmad developmentandevaluationofpolycaprolactonebasedelectrospunnanofiberscontainingtimololmaleateasasustainedreleasedevicefortreatmentofglaucomainvivoevaluationinequineeye